To Observe The Efficacy Of Bendamustine Combined With Pomalidomide And Dexamethasone In The Treatment Of Relapsed/Refractory Multiple Myeloma

Objective To observe the short-term efficacy and safety of bendamustine combined with pomalidomide and dexamethasone(BPD)in the treatment of relapsed/refractory multiple myeloma(MM).Methods A total of 30 patients with relapsed/refractory multiple myeloma admitted to the Department of Hematology of 6 tertiary hospitals in Anhui Province and the First Affiliated Hospital of Anhui from June 2020 to June 2022 were selected as the observation objects.All patients received at least one course of bendamustine combined with pomalidomide and dexamethasone.The efficacy and safety of each chemotherapy cycle were observed and evaluated.Results All patients received at least one cycle of BPD regimen.The overall response rate was 53.3%,of which 10.0%(3/30 cases)achieved complete remission,16.7%(5/30cases)achieved better partial remission,and 26.7%(8/30 cases)achieved partial remission.The overall response rate was 85.7% in patients who had received first-line treatment and 68.4% in patients who had received second-line treatment.The overall response rate was 37.5% in patients who had received three or more lines of previous therapy.The ORR of 8(26.67%)patients with high cytogenetic risk was 25%,and the ORR of 22(73.33%)patients with standard cytogenetic risk was 63.63%.Two of the eight patients with high-risk cytogenetics achieved partial response.Safety analysis showed that there were 9 cases(31.0%)of neutropenia,5 cases(16.6%)of anemia,and4 cases(13.3%)of thrombocytopenia in terms of hematology related toxicity.The most common non-hematologic toxicities were peripheral neuropathy and infection.Conclusion BPD regimen is effective and safe in the treatment of RRMM patients.